Idenix Pharmaceuticals News (NASDAQ:IDIX)

Latest Idenix Pharmaceuticals News Headlines
DateTimeSource
Headline
11/03/20098:00AMPRNUSIdenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for th
CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today that it has initiated a Phase II clinical trial evaluating IDX184, a liver-targeted nucleotide... More...>>
10/30/20098:00AMPRNUSIdenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug... More...>>
10/29/20094:05PMPRNUSIdenix Pharmaceuticals Reports Third Quarter and Nine Month 2009 Financial Results
CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30... More...>>
10/29/20094:05PMPRNUSIdenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Novartis Pharma AG has decided not to exercise its option to license IDX184, a... More...>>
10/27/20094:05PMPRNUSIdenix Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that management will present a corporate overview at the upcoming Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3rd, 2009 at 2:45 p.m. ET at the Waldorf Astoria, New York. The live and... More...>>
10/22/20094:05PMPRNUSIdenix to Host Conference Call Discussing Third Quarter 2009 Financial Results
CAMBRIDGE, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (NASDAQ:IDIX) announced today that it will report its financial results for the third quarter of 2009 on Thursday, October 29, 2009 after U.S. financial markets close. In conjunction with the issuance of the press release, Idenix management... More...>>
10/01/20094:05PMPRNUSIdenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASL
CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts on IDX184, the company's lead hepatitis C development program, have... More...>>
09/28/20094:05PMPRNUSIdenix Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
CAMBRIDGE, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that management will present a corporate overview at the upcoming JMP Securities Healthcare Focus Conference on Monday, October 5, 2009 at 8:30 a.m. ET at The New York Palace Hotel. The live and archived... More...>>
08/05/20099:15AMPRNUSIdenix Pharmaceuticals Prices Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Aug. 5 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 7,248,936 shares of its common stock at a... More...>>
07/20/20094:05PMPRNUSIdenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009... More...>>
07/20/20094:05PMPRNUSIdenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has successfully completed a three-day proof-of-concept study of IDX184. Idenix... More...>>
07/14/20094:05PMPRNUSIdenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
CAMBRIDGE, Mass., July 14 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (NASDAQ:IDIX) announced today that it will report its financial results for the second quarter of 2009 on Monday, July 20, 2009 after U.S. financial markets close. In conjunction with the issuance of the press release, Idenix management... More...>>
05/11/20094:05PMPRNUSIdenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
CAMBRIDGE, Mass., May 11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that Idenix management will present a corporate overview at the upcoming Deutsche Bank 2009 Health Care Conference on Monday, May 18, 2009 at 8:40 a.m. ET at the Intercontinental Hotel, Boston. The live and... More...>>
04/30/20094:05PMPRNUSIdenix Pharmaceuticals Reports First Quarter Financial Results
CAMBRIDGE, Mass., April 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2009. At March 31... More...>>
04/23/20097:00AMPRNUSIdenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Assoc
CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported data from its three hepatitis C development programs being presented this week at the... More...>>
04/03/20094:05PMPRNUSIdenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
CAMBRIDGE, Mass., April 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that management will present an overview of the company's three hepatitis C programs at the Canaccord Adams Hepatitis C Conference on Tuesday, April 7 at 9:45 a.m. ET at the InterContinental The Barclay New... More...>>
03/18/20094:06PMPRNUSIdenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European
CAMBRIDGE, Mass., March 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts from the company's hepatitis C antiviral discovery and development... More...>>
03/03/20094:05PMPRNUSIdenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass., March 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that management will present a corporate overview at the upcoming Barclays Capital Global Healthcare Conference on Tuesday, March 10th at 1:30 p.m. ET at the Loews Miami Beach Hotel and at the Cowen and Company... More...>>
02/17/20094:05PMPRNUSIdenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
CAMBRIDGE, Mass., Feb. 17 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the fourth quarter and year ended... More...>>
02/11/20094:30PMPRNUSIdenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
CAMBRIDGE, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (NASDAQ:IDIX) announced today that it will report its financial results for the fourth quarter of 2008 on Tuesday, February 17, 2009 after the U.S. financial markets close. In conjunction with the issuance of the press release, Idenix... More...>>


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2009 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
31 site:2us nasdaq idix091124 06:08 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 )